サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747923

ロタウイルスワクチンの世界市場

Rotavirus Vaccines

出版日
ページ情報
英文 277 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
ロタウイルスワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 277 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ロタウイルスワクチンの世界市場は2030年までに159億米ドルに達する見込み

2024年に97億米ドルと推定されるロタウイルスワクチンの世界市場は、分析期間2024-2030年にCAGR 8.5%で成長し、2030年には159億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるロタリックス・ワクチンは、CAGR 8.7%を記録し、分析期間終了時には63億米ドルに達すると予測されます。Rotateqワクチン分野の成長率は、分析期間中CAGR 6.9%と推定されます。

米国市場は27億米ドルと推定、中国はCAGR13.2％で成長予測

米国のロタウイルスワクチン市場は、2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに34億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.3%と8.1%と予測されています。欧州では、ドイツがCAGR 5.7%で成長すると予測されています。

世界の「ロタウイルスワクチン」市場- 主要動向と促進要因まとめ

なぜロタウイルスワクチン接種は小児ヘルスケアに不可欠なのか？

ロタウイルスは、衛生面や栄養面での大きな進歩にもかかわらず、世界の乳幼児における重篤な下痢性疾患の主要な原因の1つとなっています。このウイルスは感染力が非常に強く、いったん症状が出ると脱水症状のために入院が必要になることが多いです。ロタウイルスワクチンは、最も効果的な予防戦略を提供し、先進国でも開発途上国でも、死亡率、入院数、治療費を劇的に減少させる。WHOは、国の予防接種プログラムでロタウイルスの定期接種を推奨しており、その結果は説得力のあるものです。ロタウイルスワクチンを導入した国では、ロタウイルスによる入院が80％以上減少しました。現在のワクチン（ロタリックス、ロタテック、新しい熱安定性ワクチンなど）は、主に経口ワクチンであり、乳幼児への忍容性が高いです。さらに、新規参入企業は、ドロップイン・コールドチェーンという代替手段を用いて、農村部や遠隔地での接種率向上を目指しています。ロタウイルスワクチン接種の重要性は、予防だけでなく、世界の小児ヘルスケアインフラへの負担を回避することにあります。

次世代製剤と広範なアクセスモデルが世界の予防接種を牽引する？

新しいワクチン技術と製造能力の拡大が、ロタウイルス予防接種の状況を変えつつあります。最小限のコールドチェーン保管で済む熱安定性製剤は、アフリカや東南アジアの遠隔地で試験的に使用されています。さらに、スケジュールを合理化し、コンプライアンスを高めるために、単回投与製剤や新生児用製剤が開発中です。ワクチン同盟（Gavi）が推進するような官民パートナーシップの台頭により、低所得国での補助金付き配布が広まりつつあります。同様に重要なのは、インド、中国、ブラジルでコスト効率の高いジェネリック医薬品やバイオシミラーを製造する現地メーカーが台頭し、欧米製薬大手への依存度が低下していることです。ワクチンの普及率は、ロジスティクスだけでなく、介護者や地域医療従事者を対象とした教育キャンペーンによっても向上しています。科学の進歩と公平なアクセス戦略の組み合わせは、ロタウイルスに関連する罹患率をより広範かつ持続的に減少させる舞台を整えつつあります。

サーベイランスデータと実世界の結果はワクチンの進化に影響を与えるか？

ロタウイルスのワクチン戦略を改良する上で、実世界での有効性試験と継続的な疫学サーベイランスが不可欠であることが証明されています。特に複数の血清型が混在する地域では、菌株の多様性が課題であることが知られています。このため、地域に特化した混合ワクチンや二価ワクチン製剤の開発が進められています。さらに、ロタウイルスワクチンをデジタルヘルスレジストリーに統合することで、転帰の追跡、有害事象のモニタリング、アドヒアランス分析が改善されました。縦断的なデータからは、ワクチン未接種の集団でさえも、カバー率の高い地域では感染率が低下しており、集団免疫の利点が示されています。このような洞察は、ワクチンメーカーが標的を改善するのに役立つと同時に、政府が実証された効果に基づいて保健予算を再配分することを可能にしています。ロタウイルス株のゲノム配列決定の進歩と相まって、実データは次世代ワクチン革新の礎となりつつあります。

医療システム全体におけるロタウイルスワクチンの世界的拡大の原動力は？

世界のロタウイルスワクチン市場の成長は、特に予防接種資金の拡大、地域ごとの製造能力、ワクチン技術の革新など、いくつかの要因によってもたらされています。小児予防接種に対する政府の義務付けやWHOによる新型ワクチンの事前認定は、世界の市場参入を加速させています。アフリカと南アジアにおける出生率の上昇は、親やヘルスケア従事者の意識の向上と相まって、需要を強化しています。耐熱性製剤や単回経口製剤のような技術的改良により、物流の実現可能性が向上し、コストが削減されています。ユニセフやGaviを通じた助成金制度や多国間調達の枠組みは、資源の乏しい環境におけるワクチンの利用可能性を大幅に高めています。さらに、高負担国での現地臨床試験と承認により、展開が迅速化し、文化的に受け入れられやすくなっています。早期の疾病予防に重点を置く公衆衛生システムにより、ロタウイルスワクチンは世界中の定期予防接種スケジュールの定番となりつつあります。

セグメント

タイプ（Rotarix、Rotateq、Rotavin-M1、Lanzhou Lamb、その他のタイプ）、エンドユーザー（病院・クリニック、学術・調査、その他のエンドユーザー）

調査対象企業の例（合計 34注目）

  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare（Zydus Cadila）
  • Center for Research and Production of Vaccines and Biologicals（POLYVAC）
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35690

Global Rotavirus Vaccines Market to Reach US$15.9 Billion by 2030

The global market for Rotavirus Vaccines estimated at US$9.7 Billion in the year 2024, is expected to reach US$15.9 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2024-2030. Rotarix Vaccines, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Rotateq Vaccines segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.2% CAGR

The Rotavirus Vaccines market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global "Rotavirus Vaccines" Market - Key Trends & Drivers Summarized

Why Is Rotavirus Vaccination So Vital in Pediatric Healthcare?

Rotavirus remains one of the leading causes of severe diarrheal disease in infants and young children worldwide, despite major advances in sanitation and nutrition. The virus is highly contagious, and once symptomatic, often requires hospitalization due to dehydration. Rotavirus vaccines offer the most effective preventive strategy, dramatically reducing mortality rates, hospital admissions, and treatment costs in both developed and developing countries. The WHO recommends routine rotavirus immunization in national immunization programs, and the results have been compelling: countries that introduced the vaccine saw hospitalizations due to rotavirus decrease by over 80%. Current vaccines-such as Rotarix, RotaTeq, and newer heat-stable versions-are primarily oral and well-tolerated in infants. Furthermore, new entrants are aiming to improve coverage in rural and remote areas with drop-in cold chain alternatives. The critical importance of rotavirus vaccination lies not just in prevention, but in averting strain on pediatric healthcare infrastructure globally.

Are Next-Gen Formulations and Broader Access Models Driving Global Immunization?

New vaccine technologies and expanded manufacturing capabilities are reshaping the rotavirus immunization landscape. Heat-stable formulations that require minimal cold chain storage are being piloted for deployment in remote regions across Africa and Southeast Asia. Additionally, single-dose and neonatal formulations are under development to streamline scheduling and boost compliance. The rise of public-private partnerships, such as those fostered by Gavi, the Vaccine Alliance, is facilitating widespread, subsidized distribution in low-income nations. Equally important is the emergence of local manufacturers in India, China, and Brazil who are producing cost-effective generics and biosimilars, reducing dependency on Western pharma giants. Vaccine coverage is now increasing not only due to logistics but also due to targeted education campaigns aimed at caregivers and community health workers. The combination of scientific advancement and equitable access strategies is setting the stage for a broader and more sustained decline in rotavirus-related morbidity.

Can Surveillance Data and Real-World Outcomes Influence Vaccine Evolution?

Real-world efficacy studies and ongoing epidemiological surveillance are proving essential in refining vaccine strategies for rotavirus. Strain diversity is a known challenge-especially in regions where multiple serotypes co-circulate-and studies have revealed varying degrees of protection across different geographies. This has prompted development of region-specific vaccine blends and enhanced bivalent formulations. Moreover, integration of rotavirus vaccines into digital health registries has allowed for better outcome tracking, adverse event monitoring, and adherence analysis. Longitudinal data shows herd immunity benefits, with even unvaccinated populations experiencing reduced infection rates in high-coverage areas. These insights are helping vaccine makers improve targeting, while allowing governments to reallocate health budgets based on demonstrated impact. Combined with advances in genomic sequencing of rotavirus strains, real-world data is becoming a cornerstone of next-gen vaccine innovation.

What’s Driving Global Expansion of Rotavirus Vaccines Across Health Systems?

The growth in the global rotavirus vaccines market is driven by several factors, notably expanded immunization funding, regional manufacturing capabilities, and vaccine technology innovation. Government mandates for pediatric immunization and WHO prequalification of new vaccine variants are accelerating market access globally. Rising birth rates in Africa and South Asia, coupled with increased awareness among parents and healthcare workers, are strengthening demand. Technological improvements-like thermostable and single-dose oral formulations-are improving logistical feasibility and reducing costs. Subsidized pricing and multilateral procurement frameworks through UNICEF and Gavi have significantly increased vaccine availability in resource-poor settings. Additionally, local clinical trials and approvals in high-burden countries are making rollouts faster and more culturally acceptable. With public health systems focusing on early-life disease prevention, rotavirus vaccines are becoming a staple in routine immunization schedules worldwide.

SCOPE OF STUDY:

The report analyzes the Rotavirus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb, Other Types); End-Use (Hospitals & Clinics, Academic & Research, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Bharat Biotech
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare (Zydus Cadila)
  • Center for Research and Production of Vaccines and Biologicals (POLYVAC)
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vabiotech
  • Valneva SE

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rotavirus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Burden of Pediatric Diarrheal Diseases Drives Demand for Rotavirus Vaccination
    • Expanded Immunization Programs in Emerging Economies Propel Market Growth
    • World Health Organization Recommendations Strengthen the Business Case for Global Rollouts
    • Inclusion of Rotavirus Vaccines in National Immunization Schedules Expands Addressable Market
    • GAVI and UNICEF Funding Initiatives Generate Access Opportunities in Low-Income Regions
    • Advancements in Cold Chain Logistics Sustain Growth in Global Distribution
    • Rising Awareness Campaigns Around Infant Health Spur Vaccine Adoption
    • Improved Efficacy and Longer Duration of Protection Drive Preference for New Formulations
    • Ongoing Research on Combination Vaccines Throws the Spotlight on Product Innovation
    • Efforts to Reduce Child Mortality Rates Reinforce Market Demand
    • Entry of Low-Cost Manufacturers Boosts Supply in Price-Sensitive Markets
    • Regulatory Approvals of New Vaccine Variants Accelerate Market Penetration
    • Public-Private Partnerships Enhance Vaccine Delivery Infrastructure
    • Surveillance Data and Disease Burden Analytics Drive Policy and Procurement Decisions
    • Pandemic-Driven Focus on Immunization Resilience Creates Opportunities for Vaccine Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rotavirus Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rotavirus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Rotarix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Rotarix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rotateq by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Rotateq by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rotavin-M1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Rotavin-M1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lanzhou Lamb by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Lanzhou Lamb by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Academic & Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Rotavirus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Rotavirus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Rotavirus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Rotavirus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Rotavirus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Rotavirus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Rotavirus Vaccines by Type - Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Rotavirus Vaccines by Type - Percentage Breakdown of Value Sales for Rotarix, Rotateq, Rotavin-M1, Lanzhou Lamb and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Rotavirus Vaccines by End-Use - Hospitals & Clinics, Academic & Research and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Rotavirus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Academic & Research and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION